FDA panel to consider simplifying COVID-19 vaccine use
A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series and booster doses administered in the U.S. would be bivalent. The committee also is expected to discuss simplifying future COVID-19 vaccine use to authorize or approve a two-dose series for certain young children, older adults and people with compromised immunity and only one dose for all other individuals; as well as periodic updates to COVID-19 vaccines, including for use this fall.
Related News Articles
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…